Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today

#APGE Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

www.stocktitan.net/news/APGE/apogee-therape...

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering Apogee Therapeutics (Nasdaq: APGE) announced a proposed underwritten public offering of $300 million of common stock on March 23, 2026, with a 30‑day option for underwriters to purchase up to an additional $45 million.Net proceeds are intended to fund preclinical and clinical programs, manufacturing, commercial readiness, R&D, capital expenditures, working capital and general corporate purposes. The offering is subject to market conditions and will be made by prospectus supplement under an existing registration statement.

#APGE Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

www.stocktitan.net/news/APGE/apogee-therape...

Crude Oil Falls Sharply; Dell Shares Spike Higher - Apogee Therapeutics (NASDAQ:APGE), Atlantic International (NASDAQ:ATLN) Dow up 2.45%, Nasdaq up 2.46%, S&P; 500 up 2.19%. Consumer discretionary shares up 3.6%, energy stocks up 0.3%. Dell announces enhancements, BofA raises price target. Apogee up 17%, Tower Semi up 9%, Urban-gro up 46%. Atlantic Int'l down 13%, Linkers down 85%, Valneva down 37%. Oil down 8.1%, gold down 2.1%. European and Asian markets mixed.

Crude Oil Falls Sharply; Dell Shares Spike Higher Dow up 2.45%, Nasdaq up 2.46%, S&P 500 up 2.19%. Consumer discretionary shares up 3.6%, energy stocks up 0.3%. Dell announces enhancements, Bof...

#APGE #ATLN #DELL #Equities #LNKS #Mid-Day #Market #Update #News #PFE #TSEM

Origin | Interest | Match

Apogee Therapeutics, Tower Semiconductor, Norwegian Cruise Line And Other Big Stocks Moving Higher On Thursday - Advance Auto Parts (NYSE:AAP), Allogene Therapeutics (NASDAQ:ALLO) Stocks fall, Nasdaq drops 200 points. Apogee Therapeutics (APGE) rises 19.4% on positive trial data. Satellogic (SATL), YD Bio (YDES), AXT Inc (AXTI) also see gains.

Apogee Therapeutics, Tower Semiconductor, Norwegian Cruise Line And Other Big Stocks Moving Higher On Thursday Stocks fall, Nasdaq drops 200 points. Apogee Therapeutics (APGE) rises 19.4% on positi...

#AAP #ALLO #APGE #AXTI #CIEN #CWH #FSLY #IHRT #NCLH #PLAB #RIVN

Origin | Interest | Match

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results Apogee Therapeutics (NASDAQ: APGE) reported full‑year 2025 results and pipeline progress, highlighting advancing clinical programs for zumilokibart (APG777) and combination candidates.Key points: APEX Phase 2 Part A 52‑week maintenance readout expected March 2026; Part B 16‑week readout in Q2 2026; Phase 3 initiation targeted 2H 2026. Cash was $902.9M at year‑end, providing runway into 2H 2028. Positive Phase 1b asthma data and a head‑to‑head APG279 vs DUPIXENT study readout expected 2H 2026.

#APGE Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results

www.stocktitan.net/news/APGE/apogee-therape...

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results Apogee Therapeutics (NASDAQ: APGE) reported Q3 2025 results and pipeline progress on Nov 10, 2025. The company expects four clinical readouts in 2026 including APG777 Phase 1b in asthma (Q1 2026), APEX 52-week Part A maintenance data in AD (Q1 2026), APEX 16-week Part B in AD (Q2 2026), and an APG279 head-to-head interim readout vs DUPIXENT in 2H 2026.Interim Phase 1 data for APG333 showed a ~55-day half-life, biomarker suppression to six months and support for quarterly or less frequent dosing in combination APG273. The company completed a $345M offering, with pro forma cash of $913M as of Sept 30, 2025, supporting runway into 2H 2028. Q3 operating metrics: R&D $54.2M, G&A $17.1M, net loss $65.0M.

#APGE Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/APGE/apogee-therape...

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody Apogee Therapeutics (NASDAQ: APGE) reported positive interim Phase 1 results for APG333, a half-life–extended TSLP antibody, from a first‑in‑human, single‑ascending dose study in 32 healthy volunteers on Nov 10, 2025. Key findings: an optimized PK profile with an approximate 55‑day half‑life, durable suppression of eosinophils and IL‑5 out to 6 months after one dose, and tolerability up to 1,000 mg. Results support potential 3‑ to 6‑month dosing and development of a quarterly co‑formulation with APG777 (APG273).

#APGE Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

www.stocktitan.net/news/APGE/apogee-therape...

This year's PAGE pins have arrived! Orderable soon at Phillygamingexpo.com #APGE

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering Apogee Therapeutics (Nasdaq: APGE) priced an underwritten public offering to raise approximately $300 million in gross proceeds.The offering includes 6,951,221 shares of common stock at $41.00 per share and pre-funded warrants to purchase up to 365,853 shares at $40.99999 each (exercise price $0.00001), exercisable immediately. The offering is expected to close on October 10, 2025, subject to customary conditions.Underwriters have a 30-day option to purchase up to 1,097,561 additional shares. Joint book-runners include Jefferies, BofA Securities, Guggenheim Securities and TD Cowen. An automatically effective shelf registration was filed with the SEC on August 12, 2024.

#APGE Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

www.stocktitan.net/news/APGE/apogee-therape...

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering Apogee Therapeutics (Nasdaq: APGE) announced on October 8, 2025 that it has commenced a proposed underwritten public offering of shares of common stock or, for certain investors, pre-funded warrants to purchase common stock. The company said it will grant underwriters a 30-day option to buy up to an additional 15% overallotment of the shares at the public offering price, subject to market conditions and underwriting terms.Apogee intends to use net proceeds together with existing cash and marketable securities to fund preclinical studies, clinical trials, manufacturing, commercial readiness for its antibody programs, additional R&D, capital expenditures, working capital and general corporate purposes. The offering will be made by written prospectus and is subject to completion and SEC registration requirements.

#APGE Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

www.stocktitan.net/news/APGE/apogee-therape...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#DNN, #POET, #APGE, #FIVE, #CSCO

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #DNN 4.8x
2. #FTI 2.8x
3. #POET 2.6x
4. #BULL 2.4x
5. #APGE 2.2x

#OptionFlow #OptionsTrading #Trading

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis APEX Part A testing every 3- or 6-month maintenance dosing, a significant improvement versus standard of

#APGE Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/APGE/apogee-therape...

Apogee Surges 33% Premarket After Strong Phase 2 Eczema Results Apogee Therapeutics (Nasdaq: APGE) soared as much as 33% premarket after reporting positive topline data from its Phase 2 trial of APG777 in moderate-to-severe

Apogee Therapeutics #APGE shares surged pre-market after its eczema drug APG777 delivered best-in-class results in a Phase 2 trial. The IL-13 antibody hit all endpoints and could challenge Dupixent, co-developed by #sanofi ( #SNY) and #Regeneron ( #REGN)...
prismmarketview.com/apogee-surge...

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in mild-to-moderate asthma with readout expected in 1H 2026 APG279 on track to initiate Phase 1b

#APGE Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/APGE/apogee-therape...

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results Apogee Therapeutics (NASDAQ: APGE) reported significant pipeline progress and 2024 financial results. The company's Phase 2 APEX clinical trial for APG777 has exceeded enrollment in Part A, with Part B initiated ahead of schedule. Topline Part A 16-week data is expected mid-2025.Key financial highlights include $731.1 million in cash and equivalents, providing runway into Q1 2028. R&D expenses increased to $167.9 million in 2024 (vs $68.4M in 2023), while G&A expenses rose to $49.0 million (vs $24.6M in 2023). Net loss widened to $182.1 million in 2024 from $84.0 million in 2023.The company reported positive interim results for APG990, with a 60-day half-life supporting three- and six-month dosing potential. APG279 (APG777 + APG990) head-to-head study versus DUPIXENT is planned, with readout expected in H2 2026. Additional pipeline developments include progress in respiratory indications and positive interim data for APG808.

#APGE Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

www.stocktitan.net/news/APGE/apogee-therape...

Clinical Trial Breakthrough: Apogee's Novel Eczema Drug Draws Record Patient Interest Apogee's APG777 atopic dermatitis trial exceeds enrollment goals with 123 patients, fast-tracking development of potential game-changing therapy requiring 70-90% fewer injections.

#APGE Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

www.stocktitan.net/news/APGE/apogee-therape...

Apogee Therapeutics Reports Breakthrough Half-Life Data for Key Drug Candidates APG777, APG808 | APGE Stock News Apogee's R&D Day reveals promising results: APG777 achieves 77-day half-life enabling annual dosing potential, while APG808 shows strong Phase 1 data. Pipeline advances include accelerated trials.

#APGE Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

#news #StockMarket #investing

www.stocktitan.net/news/APGE/apogee-therape...

Apogee Therapeutics Sets R&D Day to Unveil APG808 Clinical Trial Results, Pipeline Updates | APGE Stock News Apogee Therapeutics will present interim Phase 1 results for APG808, showcase pipeline developments, and feature expert insights on atopic dermatitis and respiratory treatments.

#APGE Apogee Therapeutics Announces Agenda for Virtual R&D Day

#stocks #StockMarket #investing

www.stocktitan.net/news/APGE/apogee-therape...

#APGE Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

www.stocktitan.net/news/APGE/apogee-therape...